Compliance baked into the design core: On AI in life sciences with Florian Schnappauf
When it comes to artificial intelligence, the tables are turning and there is a shift in considering it a hype to understanding that AI is a real necessity. And 2025 is becoming a turning point wherein practical, embedded AI begins to scale.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Florian Schnappauf, VP, enterprise commercial strategy Europe, at Veeva Systems.
The conversation covers commercial model evolution, precision engagement, the importance of quality data in a personalisation strategy, and – of course – compliance.
You can also listen to episode 197a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
--------
19:18
--------
19:18
Putting patients and their families first: Dr Corina Dutcus, post-ASCO 2025
At ASCO 2025, Eisai presented data from its oncology portfolio, including in hepatocellular carcinoma and endometrial cancer.
In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the company’s continued commitment to innovation in the oncological field.
Tune in to this and other ASCO 2025 conversations here.
You can also listen to episode 196a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
--------
18:40
--------
18:40
Enhancing anti-tumour activity: A post-ASCO conversation with Dan Schmitt
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases.
At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resistance pathways and immune mechanisms in previously untreated patients with mPDAC.
In a post-ASCO pharmaphorum podcast, Dan Schmitt, CEO of Actuate, discussed the data, as well as the Congress as a whole, and his hopes for the future of oncology more generally.
You can also listen to episode 195a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
--------
28:19
--------
28:19
Redefining the Future of Melanoma Treatment: Scancell's Bold Step Forward
Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Phillip L’Huillier, CEO of Scancell, about how the company develops novel immunotherapy products for the treatment of multiple cancers, as well as its recently announced partnership with the NHS Cancer Vaccine Launch Pad, and latest data release from the Phase 2 clinical SCOPE study in melanoma.
L’Huillier discusses their melanoma-specific vaccine, and more broadly this pivotal time in immuno-oncology and possibilities on the near horizon.
You can also listen to episode 194a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
--------
19:05
--------
19:05
Why Datavant bought Aetion, and what comes next, with Arnaub Chatterjee
Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the real-world data space. Now that the acquisition has closed, the pharmaphorum podcast welcomes Arnaub Chatterjee, president and general manager of life sciences at Datavant, to discuss what that integration will look like -- and what the implications are for the pharma industry.
Chatterjee discusses how the acquisition came about and what the strategic fit looks like between the two organisations, as well as how they will complement each other going forward.
While the focus is on the news and what it means, Chatterjee and host Jonah Comstock also delve into some larger topics around real-world data in life sciences – how it’s being used, how regulators are responding to it, some of the biggest roadblocks holding the space back, and what the competitive landscape looks like. And Chatterjee shares his vision for what the future of data discovery, linkage, and analytics in life sciences could look like.
Tune in for the full discussion on this exciting industry development.
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
Ireland